Related Experiment Videos
[Clinical experience with flomoxef in the pediatric field]
T Sekiguchi1, T Okamoto, K Ohara
1Department of Pediatrics, Takamatsu Red Cross Hospital.
The Japanese Journal of Antibiotics
|August 1, 1987
Summary
Flomoxef (FMOX) demonstrated high efficacy in treating pediatric bacterial infections, with 18 of 21 children showing good clinical responses. This antibiotic successfully eradicated all 17 bacterial strains isolated, with minimal side effects observed.
Area of Science:
- Pediatric Infectious Diseases
- Bacteriology
- Clinical Pharmacology
Context:
- Acute bacterial infections in children pose significant health challenges.
- Effective antibiotic therapy is crucial for pediatric patient outcomes.
- Flomoxef (FMOX) is a newer generation antibiotic with a broad spectrum of activity.
Purpose:
- To evaluate the clinical efficacy and safety of intravenous Flomoxef (FMOX) in pediatric patients.
- To assess the microbiological eradication rates of bacterial pathogens in children treated with FMOX.
- To determine the tolerability and side effect profile of FMOX in a pediatric population.
Summary:
- A total of 21 pediatric patients with acute bacterial infections received intravenous Flomoxef (FMOX).
- Infections treated included bronchopneumonia, urinary tract infections, meningitis, and skin infections.
- Clinical cure was observed in 18 patients (85.7%), and all 17 isolated bacterial strains were eradicated.
Impact:
- Flomoxef (FMOX) shows promise as a valuable therapeutic option for various bacterial infections in children.
- The study supports the use of FMOX in pediatric settings due to its favorable efficacy and safety profile.
- Further research may explore FMOX's role in combating antibiotic resistance in pediatric infections.